Structure Therapeutics (GPCR) Cash from Operations (2022 - 2026)

Structure Therapeutics' Cash from Operations history runs 5 years deep, the most recent figure standing at 15234000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 129.17% year-over-year to 15234000.0 in Q1 2026; TTM through Mar 2026 was 154736000.0, a 14.8% decrease from a year earlier, with the FY2025 full-year figure at 222199000.0, down 90.51% from the prior year.
• Cash from Operations advanced to 15234000.0 in Q1 2026 per GPCR's latest filing, from 64416000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 15234000.0 in Q1 2026 and bottomed at 64416000.0 in Q4 2025.
• The 5-year median for Cash from Operations is 20557000.0 (2023), against an average of 26424058.82.
• Across the five-year window, Cash from Operations plunged 158.92% in 2025 and jumped 129.17% in 2026, its largest moves.
• Year by year, Cash from Operations stood at 12026000.0 in 2022, then sank by 80.68% to 21729000.0 in 2023, then sank by 67.83% to 36467000.0 in 2024, then slumped by 76.64% to 64416000.0 in 2025, then soared by 123.65% to 15234000.0 in 2026.
• Per Business Quant, the three latest GPCR Cash from Operations figures stand at 15234000.0 (Q1 2026), 64416000.0 (Q4 2025), and 50996000.0 (Q3 2025).